

JACQUELINE BOSTON

Plaintiff,

VS.

BOEHRINGER INGELHEIM
PHARMACEUTICALS, INC.,
BOEHRINGER INGELHEIM
CORPORATION, BOEHRINGER
INGELHEIM USA CORPORATION, AND
BOEHRINGER INGELHEIM
VETMEDICA, INC.

§

§

22

202

so

2

 \mathcal{S}

S

3

32

 ∞ ∞

Cause No. 3:12-cv-00610-JPG-SCW

COMPLAINT

PARTIES

2. Boehringer Ingelheim Pharmaceuticals, Inc. (“Boehringer”) is a Delaware corporation which has its principal place of business at 900 Ridgebury Road, Ridgefield, Connecticut 06877. Boehringer may be served at CT Corporation System, 208 South LaSalle Street, Suite 814, Chicago, Illinois 60604. Boehringer has conducted business and derived substantial revenue from within the State of Illinois.

3. Boehringer Ingelheim Vetmedica, Inc. (“Boehringer Vet”) is a Delaware corporation which has its principal place of business at 2621 North Belt Highway, St. Joseph, MO 64506. Boehringer Vet may be served at CT Corporation System, 208 South LaSalle Street, Suite 814, Chicago, Illinois 60604. Boehringer Vet has conducted business and derived substantial revenue from within the State of Illinois.

4. Boehringer Ingelheim Corporation (“Boehringer Co”) is a Delaware corporation which has its principal place of business at 900 Ridgebury Road, Ridgefield, Connecticut 06877. Boehringer Co. may be served at CT Corporation System, One Corporate Center, Hartford, Connecticut 06103. Boehringer Co. has conducted business and derived substantial revenue from within the State of Illinois.

5. Boehringer Ingelheim USA Corporation (“Boehringer USA”) is a Delaware corporation which has its principal place of business at 900 Ridgebury Road, Ridgefield, Connecticut 06877. Boehringer USA may be served at CT Corporation System, One Corporate Center, Hartford, Connecticut 06103. Boehringer USA has conducted business and derived substantial revenue from within the State of Illinois.

JURISDICTION AND VENUE

6. This Court has jurisdiction over this action pursuant to 28 USC §1332 because the amount in controversy as to Plaintiff exceeds \$75,000.00, exclusive of interest and costs, and because Defendants are incorporated and have their principal places of business in states other than the state in which the named Plaintiff resides.

7. This Court has supplemental jurisdiction over the remaining common law and state claims pursuant to 28 U.S.C. § 1367.

8. Venue of this case is proper in the Southern District of Illinois pursuant to 28 U.S.C. § 1391(b)(1) because all Defendants are residents of this state.

9. Venue is further proper in this Court pursuant to 28 U.S.C. § 1391 because a substantial part of the events giving rise to Plaintiff's claims occurred, in part, in the Southern District of Illinois.

FACTUAL BACKGROUND

Background of the Case

10. At all relevant times, Defendants, directly or through their agents, apparent agents, servants or employees designed, manufactured, marketed, advertised, distributed, promoted, labeled, tested and sold Pradaxa® (dabigatran etexilate mesylate).

11. Pradaxa® is a direct thrombin inhibitor that is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Patients with atrial fibrillation have an increased risk of stroke.

12. Pradaxa® was approved by the Food and Drug Administration ("FDA") on October 19, 2010. The FDA approved two dosages: 75 mg and 150 mg, to be taken twice daily. Pradaxa® was the first anticoagulation medication approved in the U.S. in more than 50 years for patients with non-valvular atrial fibrillation.

13. Prior to the FDA's approval of Pradaxa®, warfarin was the only oral anticoagulation available in the U.S. for reducing stroke and systemic embolism in patients with atrial fibrillation. Unlike patients who use Pradaxa®, users of warfarin must follow dietary restrictions and regularly monitor their blood levels (INR) by undergoing blood tests and potentially adjusting the dose of their medication.

Defendants' over promotion of Pradaxa®

14. Defendants promoted Pradaxa® as a novel medicine for patients with non-valvular atrial fibrillation. Defendants' marketing campaign for Pradaxa® included promoting it as being more effective than warfarin in preventing stroke and systemic embolism, providing a convenient alternative to warfarin therapy because it does not require blood monitoring or dose adjustments, and does not require any dietary restrictions.

15. Defendants spent significant money in promoting Pradaxa®, which included \$67,000,000.00 spent during 2010 (although Pradaxa® was not approved for sale until October 19, 2010).¹

16. During 2011, Defendants reportedly undertook 1.5 million Pradaxa® "detailing sessions" (marketing/sales visits by Defendants' sales force) with U.S. primary care physicians, internists, group practitioners, cardiologists, and practice nurses, spending approximately \$464,000,000.00 during this 12 month period to promote Pradaxa® in the United States.²

17. As part of their marketing of Pradaxa®, Defendants widely disseminated direct-to-consumer advertising campaigns that were designed to influence patients, including Plaintiff, to make inquiries to their prescribing physician about Pradaxa® and/or request prescriptions for Pradaxa®.

18. In the course of these direct to consumer advertisements, Defendants overstated the efficacy of Pradaxa® with respect to preventing stroke and systemic embolism, failed to adequately disclose to patients that there is no drug, agent or means to reverse the anticoagulation effects of Pradaxa®, and that such irreversibility could have permanently disabling, life-threatening and fatal consequences.

¹ Deborah Weinstein, *Study: Sales Support is Dwindling, Not Dead*, March 14, 2012, Medical Marketing and Media.

² Id.

19. Prior to Plaintiff's prescription of Pradaxa®, Plaintiff became aware of the promotional materials described herein.

20. Prior to Plaintiff's prescription of Pradaxa®, Plaintiff's prescribing physician received promotional materials and information from sales representatives of Defendants that Pradaxa® was more effective than warfarin in reducing strokes in patients with non-valvular atrial fibrillation and was more convenient, without also adequately informing prescribing physicians that there was no reversal agent that could stop or control bleeding in patients taking Pradaxa®.

21. At all times relevant hereto, Defendants also failed to warn emergency room doctors, surgeons and other critical care medical professionals that unlike generally-known measures taken to treat and stabilize bleeding in users of warfarin, there is no effective agent to reverse the anticoagulation effects of Pradaxa®, and therefore no effective means to treat and stabilize patients who experience uncontrolled bleeding while taking Pradaxa®.

22. At all times relevant to this action, The Pradaxa® Medication Guide, prepared and distributed by Defendants and intended for U.S. patients to whom Pradaxa® has been prescribed, failed to warn and disclose to patients that there is no agent to reverse the anticoagulation effects of Pradaxa® and that if serious bleeding occurs, it may be irreversible, permanently disabling, and life-threatening.

23. From October 2010 until the end of March 2011, approximately 272,119 prescriptions for Pradaxa® were written in the United States. During that same period, there were 932 Pradaxa®-associated "Serious Adverse Event" ("SAE") Medwatch reports filed with the U.S. Food and Drug Administration, including at least 120 deaths and over 500 reports of severe, life-threatening bleeding.

24. From April 1 until the end of June 2011, there were an additional 856 Pradaxa®-associated “SAE” Medwatch reports filed with the U.S. Food and Drug Administration including at least 117 deaths and over 510 reports of severe, life-threatening bleeding.

25. During the Defendants’ 2011 fiscal year, worldwide Pradaxa® sales eclipsed the \$1 billion threshold, achieving what is commonly known in the pharmaceutical industry as “blockbuster” sales status.³

26. Defendants original labeling and prescribing information for Pradaxa®:

- a. failed to disclose in the “Warnings” Section that there is no drug, agent or means to reverse the anticoagulation effects of Pradaxa®;
- b. failed to advise prescribing physicians, such as the Plaintiff’s physician, to instruct patients that there was no agent to reverse the anticoagulant effects of Pradaxa®;
- c. failed to investigate, research, study and consider, fully and adequately, patient weight as a variable factor in establishing recommended dosages of Pradaxa®;
- d. failed to investigate, research, study and define, fully and adequately, the safety profile of Pradaxa®;
- e. failed to provide adequate warnings about the true safety risks associated with the use of Pradaxa®;
- f. failed to warn that it is difficult or impossible to assess the degree and/or extent of anticoagulation in patients taking Pradaxa®;

³ Heide Oberhauser-Aslan and Tapan Sharma, *Boehringer Sees Sales Rising Further as 2011 Profits Surge* April 24, 2012 [WSJ.com](http://www.wsj.com)

- g. failed to provide adequate instructions on how to intervene and/or stabilize a patient who suffers a bleed while taking Pradaxa®;
- h. failed to provide adequate warnings regarding the need to assess renal functioning prior to starting a patient on Pradaxa® and to continue testing and monitoring of renal functioning periodically while the patient is on Pradaxa®;
- i. failed to provide adequate warnings and information related to the increased risks of bleeding events associated with aging patient populations of Pradaxa® users;
- j. failed to provide adequate warnings regarding the increased risk of gastrointestinal bleeds in those taking Pradaxa®, especially, in those patients with a prior history of gastrointestinal issues and/or upset;
- k. failed to include a “**BOXED WARNING**” about serious bleeding events associated with Pradaxa®;
- l. failed to include a “**Bolded Warning**” about serious bleeding events associated with Pradaxa®; and
- m. in their “Medication Guide” intended for distribution to patients to whom Pradaxa® has been prescribed, Defendants failed to disclose to patients that there is no drug, agent or means to reverse the anticoagulation effects of Pradaxa® and that if serious bleeding occurs, such irreversibility could have permanently disabling, life-threatening or fatal consequences.

27. During March, 2011, Defendants modified the U.S. labeling and prescribing information for Pradaxa®, which included additional information regarding the use of Pradaxa® in patients taking certain medications. Despite being aware of: (I) serious, and sometimes fatal,

irreversible bleeding events associated with the use of Pradaxa®; (II) almost 1800 SAE Medwatch reports filed with the U.S. Food and Drug Administration, including at least 237 deaths and over 1,000 reports of severe, life-threatening bleeding, Defendants nonetheless failed to provide adequate disclosures or warnings in their label as detailed in Paragraphs 26 (a – m).

28. On July 1, 2011, Pradaxa® was approved for sale in New Zealand with lower dosing (lowered from 150mg to 110mg twice a day) required for patients over 80 years of age and recommended for patients with moderate renal impairment.

29. On July 25, 2011, the Archives of Internal Medicine published *The Use of Dabigatran [Pradaxa®] in Elderly Patients*. [Vol 171, No. 14] which concluded that “The risk of major overdosage of...[Pradaxa®] in this [elderly] population is, however, much increased owing to frequent renal function impairment, low body weight, drug interactions that cannot be detected with a routine coagulation test and no antagonist available.”

30. On January 21, 2011, Pradaxa® (under the brand name Prazaza®), in 75mg and 110mg doses only, is approved for sale in Japan to treat non-valvular atrial fibrillation.

31. On August 11, 2011, Japan’s pharmaceutical regulatory authority announced that it was requiring a “**BOXED WARNING**” be added to Pradaxa® (marketed as Prazaza® in Japan) to call attention to reports of severe hemorrhages in patients treated with Pradaxa® (Prazaza®).

32. On September 1, 2011, the New Zealand pharmaceutical regulatory authority issued a “Prescriber Update” entitled “Dabigatran – Is there a Bleeding Risk” in which physicians were alerted that Pradaxa® had a higher incidence of gastrointestinal bleeds than warfarin and that there was no reversal agent to neutralize the anticoagulation effects of Pradaxa®. A follow-up report issued in December 2011, indicated that among 10,000 New

Zealanders who had taken Pradaxa®, there were 78 reports of serious bleeding events associated with Pradaxa® including 60 reports of gastrointestinal and rectal bleeding. Among the 78 serious events were 10 patient deaths and 55 hospitalizations. Three months later in March, 2012 the New England Journal of Medicine published two letters from physicians in New Zealand addressing bleeding events associated with Pradaxa®. In one letter, physicians wrote, “We are concerned that the potential risks of this medication are not generally appreciated. The serious consequences of a lack of an effective reversal agent should not be underestimated.”

33. During November, 2011, Defendants modified the U.S. labeling and prescribing information for Pradaxa® adding additional information regarding the use of Pradaxa® in patients with kidney disease despite being aware of: (I) serious, and sometimes fatal, irreversible bleeding events associated with the use of Pradaxa®; (II) the July 25, 2011 article in the *Archives of Internal Medicine*; (III) the addition of a “**BOXED WARNING**” to Pradaxa® in Japan; and, (IV) the questions being raised by physicians in New Zealand about serious bleeding events associated with Pradaxa®, Defendants nonetheless failed to provide adequate disclosures or warnings in their label as detailed in Paragraphs 26 (a – m).

34. On December 7, 2011, the U.S. Food and Drug Administration issued a Drug Safety Communication announcing that it was undertaking a “Drug Safety Review” of Post-Marketing Reports of Serious Bleeding Events with the anticoagulant Pradaxa. The purpose of the FDA’s review is to determine if serious bleeding events associated with the use of Pradaxa® are more common than expected based on the Defendants’ data submitted to the FDA.

35. As of December 31, 2011, the U.S. Food and Drug Administration received over 500 reports of deaths of people in the U.S. linked to Pradaxa® which, at that point, had been available in the U.S. for approximately 14 months. In addition, there were over 900 reports of

gastrointestinal hemorrhages, over 300 reports of rectal hemorrhages, and over 200 reports of cerebrovascular accidents suffered by U.S. citizens associated with Pradaxa®.

36. In January, 2012, the Defendants modified the U.S. labeling and prescribing information for Pradaxa®. Despite being aware of: (i) serious, and sometimes fatal, irreversible bleeding events associated with the use of Pradaxa®; (ii) the July 25, 2011 article in the *Archives of Internal Medicine*; (iii) the addition of a “**BOXED WARNING**” to Pradaxa® in Japan; (iv) the questions being raised by physicians in New Zealand about serious bleeding events associated with Pradaxa®; and (v) the Drug Safety Communication published by the FDA in December, 2011, Defendants nonetheless failed to provide adequate disclosures or warnings in their label as detailed in Paragraphs 26 (a – m).

37. During March 2012, in response to a directive from Health Canada, the governmental agency responsible for regulating pharmaceuticals in Canada, the Defendants’ Canadian affiliate issued a “Dear Healthcare Provider” letter in which it advised Canadian healthcare providers of certain risks associated with the use of Pradaxa® (marketed as Pradax® in Canada) in elderly patients and patients with impaired kidney function and prosthetic heart valves. No such similar communication was sent to healthcare providers in the United States.

38. In April 2012, the Defendants modified the U.S. labeling and prescribing information for Pradaxa®. Despite being aware of: (i) serious, and sometimes fatal, irreversible bleeding events associated with the use of Pradaxa®; (ii) the July 25, 2011 article in the *Archives of Internal Medicine*; (iii) the addition of a “**BOXED WARNING**” to Pradaxa® in Japan; (iv) the questions being raised by physicians in New Zealand about serious bleeding events associated with Pradaxa®; (v) the Drug Safety Communication published by the FDA in December, 2011; and (vi) the “Dear Healthcare Provider” letter Defendants were required to

provide in Canada, Defendants nonetheless failed to provide adequate disclosures or warnings in their label as detailed in Paragraphs 26 (a – m).

39. At all times relevant hereto, Defendants failed to warn emergency room doctors, surgeons and other critical care medical professionals that unlike generally-known measures taken to treat and stabilize bleeding that occurs in the presence of warfarin, there is no effective agent to reverse the anticoagulation effects of Pradaxa® and therefore no effective means to treat and stabilize patients who experience uncontrolled bleeding while taking Pradaxa®.

Plaintiff's use of Pradaxa® and resulting injuries

40. As a result of Defendants' claims regarding the effectiveness, safety, and benefits of Pradaxa®, Plaintiff and Plaintiff's physicians were unaware, and could not have reasonably known or have learned through reasonable diligence that Plaintiff would be exposed to the risk of excessive and/or uncontrollable bleeding and the other risks and injuries described herein.

41. Therefore, Plaintiff was prescribed Pradaxa® in September, 2011 for treatment of non-valvular atrial fibrillation. Shortly thereafter, Plaintiff suffered a severe gastrointestinal bleed on or about September 27, 2011, causing her to be hospitalized at Memorial Hospital for a period of 12 days. Plaintiff experienced uncontrollable bleeding which was caused and/or worsened by her use of Pradaxa®.

42. Prior to Plaintiff's use of Pradaxa®, Defendants knew or should have known that the original labeling of the drug did not adequately warn Plaintiff of the risks associated with using the drug as described above.

43. Prior to Plaintiff's use of Pradaxa®, Defendants knew or should have known of the defective nature of Pradaxa® and persons who were prescribed and ingested Pradaxa® for even a brief period of time, including the Plaintiff, were at increased risk for developing life-

threatening bleeds. Defendants, through their affirmative misrepresentations and omissions, concealed from Plaintiff and Plaintiff's physicians the true and significant risks associated with Pradaxa® use.

44. Plaintiff was unaware of the increased risk for developing life-threatening injuries as compared to warfarin. Had Plaintiff and/or Plaintiff's healthcare provider known of the risks and dangers associated with Pradaxa®, as well as the lack of additional benefits, and had Defendants provided adequate warnings that there is no agent to reverse the anticoagulation effects of Pradaxa®, Plaintiff Jacqueline Boston would not have used Pradaxa®.

45. As a direct and proximate result of using Pradaxa®, Plaintiff has suffered severe personal injuries, physical pain and mental anguish, including diminished enjoyment of life, as well as the need for lifelong medical treatment, monitoring and/or medications, and fear of developing any of the above named health consequences all resulting from Plaintiff's ingestion of Pradaxa®.

CAUSES OF ACTION

COUNT I **STRICT LIABILITY-FAILURE TO WARN**

46. Plaintiff hereby incorporates by reference all preceding paragraphs as if fully set forth herein.

47. At all times relevant to this suit, Defendants engaged in the business of designing, manufacturing, testing, marketing, labeling and placing into the stream of commerce Pradaxa® for sale to, and use by, members of the public.

48. At all times relevant to this suit, the dangerous propensities of Pradaxa® were known to Defendants, or were reasonably and scientifically knowable to them, through appropriate research and testing by known methods, at the time they distributed, supplied, or sold

their respective product, and not known to ordinary physicians who would be expected to prescribe the drug for their patients.

49. The Pradaxa® manufactured by Defendants reached Plaintiff without substantial change and was ingested as directed.

50. Defendants marketed Pradaxa® in multiple ways, including but not limited to direct-to-consumer advertisements, which were misleading in that Defendants overstated the safety and efficacy of Pradaxa® and understated its risks.

51. The Pradaxa® was defective and unreasonably dangerous in that the labeling was insufficient to adequately warn physicians and users of the increased risk of excessive and/or uncontrollable bleeding.

52. As a direct and proximate result of the actions and inactions of the Defendants as set forth above, Plaintiff was exposed to Pradaxa® and suffered personal injuries, economic and non-economic damages including pain and suffering.

53. Defendants' actions and omissions as identified in this Complaint show that Defendants acted maliciously and/or intentionally disregarded Plaintiff Jacqueline Boston's rights so as to warrant the imposition of punitive damages.

COUNT II
STRICT PRODUCTS LIABILITY - DESIGN DEFECT

54. Plaintiff hereby incorporates by reference all preceding paragraphs as if fully set forth herein.

55. Defendants are the manufacturers, designers, distributors, sellers and suppliers of Pradaxa®, who sold Pradaxa® in the course of business.

56. The Pradaxa® manufactured, designed, sold, marketed, distributed, supplied and/or placed in the stream of commerce by Defendants was expected to and did reach the consumer without any alterations or changes.

57. The Pradaxa® administered to Plaintiff was defective in design or formulation in at least the following respects:

- a. When it left the hands of the Defendants, this drug was unreasonably dangerous to an extent beyond that which could reasonably be contemplated by Plaintiff or Plaintiff's physicians;
- b. Any benefit of this drug was outweighed by the serious and undisclosed risks of its use when prescribed and used as the Defendants intended;
- c. The dosages and/or formulation of Pradaxa® sold by the Defendants was unreasonably dangerous;
- d. There are no patients for whom the benefits of Pradaxa® outweighed the risks;
- e. The product was not made in accordance with the Defendants' specifications or performance standards;
- f. There are no patients for whom Pradaxa® is a safer and more efficacious drug than other drug products in its class; and/or
- g. There were safer alternatives that did not carry the same risks and dangers that Defendants' Pradaxa® had.

58. The Pradaxa® administered to Plaintiff was defective at the time it was distributed by the Defendants or left their control.

59. The foreseeable risks associated with the design or formulation of the Pradaxa® include, but are not limited to, the fact that the design or formulation of Pradaxa® is more dangerous than a reasonably prudent consumer would expect when used in an intended or reasonably foreseeable manner, and/or did not have the claimed benefits.

60. The defective and unreasonably dangerous design and marketing of Pradaxa® was a direct, proximate and producing cause of Plaintiff's injuries and damages. Under strict products liability theories set forth in Restatement (Second) of Torts, Defendants are liable to Plaintiff for all damages claimed in this case.

61. As a direct, legal, proximate, and producing result of the defective and unreasonably dangerous condition of Pradaxa®, Plaintiff suffered personal injuries, economic and non-economic damages, including pain and suffering.

62. Defendants' actions and omissions as identified in this Complaint show that Defendants acted maliciously and/or intentionally disregarded Plaintiff Jacqueline Boston's rights so as to warrant the imposition of punitive damages.

COUNT III **NEGLIGENCE**

63. Plaintiff hereby incorporates by reference all of the above allegations as if fully set forth herein.

64. Defendants owed a duty to the general public and specifically to the Plaintiff to exercise reasonable care in the design, study, development, manufacture, promotion, sale, labeling, marketing and distribution of Pradaxa® at issue in this lawsuit.

65. Defendants breached their duty and failed to exercise reasonable care in the developing, testing, designing and manufacturing of Pradaxa® because, it was capable of causing serious personal injuries such as those suffered by Plaintiff during foreseeable use.

66. Defendants breached their duty and also failed to exercise reasonable care in the marketing of Pradaxa® because they failed to warn, that as designed, Pradaxa® was capable of causing serious personal injuries such as those suffered by Plaintiff during foreseeable use.

67. Defendants breached their duty and also failed to exercise ordinary care in the labeling of Pradaxa® and failed to issue to consumers and/or their health care providers adequate warnings of the risk of serious bodily injury or death due to the use of Pradaxa®. Moreover, Defendants over-promoted the benefits of Pradaxa® for anticoagulation therapy in patients suffering from atrial fibrillation and understated the risk of excessive and/or uncontrollable bleeding.

68. Defendants breached their duty and were negligent by, but not limited to, the following actions, misrepresentations, and omissions toward Plaintiff:

- a. In disseminating information to Plaintiff and Plaintiff's physicians that was negligently and materially inaccurate, misleading, false, and unreasonably dangerous to patients such as Plaintiff;
- b. Failing to conduct adequate pre-clinical and clinical testing and post-marketing surveillance to determine the safety of Pradaxa®;
- c. Failing to design and/or manufacture a product that could be used safely due to the lack of a known reversal agent; and
- d. In designing, manufacturing, and placing into the stream of commerce a product which was unreasonably dangerous for its reasonably foreseeable use, which Defendant knew or should have known could cause injury to Plaintiff.

69. Despite the fact that Defendants knew or should have known that Pradaxa® posed a serious risk of bodily harm to consumers and/or did not provide any additional benefits, Defendants continued to manufacture and market Pradaxa® for use by consumers.

70. Defendants knew or should have known that consumers, including Plaintiff Jacqueline Boston, would foreseeably suffer injury as a result of Defendants' failure to exercise ordinary care as described above.

71. Defendants' failure to exercise reasonable care in the design, dosing information, marketing, warnings, labeling, and/or manufacturing of Pradaxa® was a proximate cause of Plaintiff's injuries and damages.

72. Defendants' conduct as described above, including but not limited to its failure to adequately test Pradaxa®, to provide adequate warnings, and its continued manufacture, sale and marketing of the product when it knew or should have known of the serious health risks it created, evidences actions and/or intentional disregard of the rights of Plaintiff Jacqueline Boston so as to warrant the imposition of punitive damages.

COUNT IV
NEGLIGENT MISREPRESENTATION AND/OR FRAUD

73. Plaintiff hereby incorporates by reference all of the above allegations as if fully set forth herein.

74. Defendants represented that Pradaxa® was just as safe or safer and as effective or more effective than other anticoagulation alternatives and had additional benefits compared to other anticoagulation medications available on the market.

75. Defendants made these misrepresentations and actively concealed adverse information at a time when the Defendants knew, or should have known, that Pradaxa® had defects, dangers, and characteristics that were other than what Defendants had represented to

Plaintiff and the health care industry generally. Specifically, Defendants misrepresented to and/or actively concealed from Plaintiff and the consuming public, among other things, that:

- a. Pradaxa® had statistically significant increases in irreversible bleeds and other side effects which could result in serious, permanent injury or death;
- b. Pradaxa® had not been fully or adequately tested;
- c. Pradaxa® does not have any known reversal agents;
- d. Pradaxa® bleeds cannot be stopped or controlled by any effective medical processes or medical intervention;
- e. Failed to warn that it is difficult or impossible to assess the degree and/or extent of anticoagulation in patients taking Pradaxa®; and
- f. Pradaxa® was not as safe as blood thinners such as warfarin.

76. Defendants negligently and/or intentionally misrepresented or omitted this information in their product labeling, promotions and advertisements and instead labeled, promoted and advertised their product as safer and more effective than other types of anticoagulation alternatives and understated the risk of excessive and/or uncontrollable bleeding associated with Pradaxa®.

77. The aforementioned misrepresentations were untrue and misleading.

78. Defendants knew or should have known that these representations were false and made the representations with the intent that Plaintiff and/or Plaintiff's prescribing physicians would rely on them, leading to the use of Pradaxa®.

79. At the time of Defendants' fraudulent misrepresentations, Plaintiff and/or Plaintiff's prescribing physicians were unaware of the falsity of the statements being made and believed them to be true. Plaintiff and/or Plaintiff's prescribing physicians justifiably relied on

and/or were induced by the misrepresentations and/or active concealment and relied on the absence of safety information, which Defendants did suppress, conceal or failed to disclose, to Plaintiff's detriment.

80. As a direct and proximate result of the fraudulent acts and omissions, suppression and misrepresentation of Defendants, Plaintiff suffered personal injuries, economic and non-economic damages, including pain and suffering.

81. Defendants' actions and omissions as identified in this Complaint demonstrate malicious actions and/or intentional disregard of Plaintiff's rights so as to warrant the imposition of punitive damages.

COUNT V
BREACH OF EXPRESS WARRANTY

82. Plaintiff incorporates by reference each preceding paragraph as though set forth fully at length herein.

83. Defendants expressly warranted, through their direct-to-consumer marketing, label, and sales representatives, that Pradaxa® was a safe and effective prescription blood thinner. The safety and efficacy of Pradaxa® constitute a material fact in connection with the marketing, promotion, and sale of Pradaxa®.

84. Pradaxa® manufactured and sold by Defendants did not conform to these express representations because it caused serious injury to consumers when taken in recommended dosages.

85. As a direct and proximate result of Defendants' breach of warranty, Plaintiff Jacqueline Boston has suffered harm, damages and economic loss and will continue to suffer such harm, damages and economic loss in the future.

86. Defendants' actions and omissions as identified in this Complaint demonstrate malicious actions and/or intentional disregard of Plaintiff Jacqueline Boston's rights so as to warrant the imposition of punitive damages.

COUNT VI
BREACH OF IMPLIED WARRANTY

87. Plaintiff incorporates by reference each preceding paragraph as though set forth fully at length herein.

88. At the time Defendants researched, developed, designed, tested, manufactured, inspected, labeled, distributed, marketed, promoted, sold, and/or otherwise released Pradaxa® into the stream of commerce, Defendants knew of the use for which Pradaxa® was intended and impliedly warranted the product to be of merchantable quality and safe for such use.

89. Defendants breached their implied warranties of the Pradaxa® product sold to Plaintiff because this product was not fit for its common, ordinary, and intended use.

90. As a direct, foreseeable and proximate result of Defendants' breaches of implied warranties, Plaintiff suffered grievous bodily injury and consequential economic and other losses, as described above, when Plaintiff ingested Pradaxa®, in reasonable reliance upon the implied warranties.

91. Defendants' actions and omissions as identified in this Complaint demonstrate malicious actions and/or intentional disregard of Plaintiff Jacqueline Boston's rights so as to warrant the imposition of punitive damages.

COUNT VII
NEGLIGENCE PER SE - DEFENDANTS' VIOLATION OF 21 U.S.C. §§ 331(a) & 352

92. Plaintiff hereby incorporates by reference all of the above allegations as if fully set forth herein.

93. As part of their duty to exercise reasonable care, Defendants were obligated to follow public laws and regulations enacted and promulgated to protect the safety of persons such as Plaintiff, including 21 U.S.C. §§ 331(a) & 352, and other statutes and regulations, which make it unlawful to misbrand prescription drug products.

94. The labeling, including package inserts, for Pradaxa® failed to conform to the requirements of 21 U.S.C. § 352, including subsections (a), (c), and (t), and the requirements of 21 C.F.R. § 201.100(c)(1), and, therefore, violated 21 U.S.C. § 331(a), which prohibits "[t]he introduction or delivery for introduction into interstate commerce of any food, drug, device, or cosmetic that is adulterated or misbranded."

95. Specifically, the product label and package insert for Pradaxa® is misbranded within the meaning of 21 U.S.C. § 352(a) and (f) because it was false and misleading and failed to give adequate warnings and directions for use by physicians who prescribe Pradaxa®.

96. Pradaxa® is misbranded pursuant to 21 U.S.C. § 352 because words, statements, or other information required by or under authority of chapter 21 U.S.C. § 352 are not prominently placed thereon with such conspicuousness and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

97. Pradaxa® is misbranded pursuant to 21 U.S.C. § 352 because the labeling does not bear adequate directions for use, and/or the labeling does not bear adequate warnings against use where its use may be dangerous to health or against unsafe dosage or methods or duration of administration or application, in such manner and form as are necessary for the protection of users.

98. Pradaxa® is misbranded pursuant to 21 U.S.C. § 352 because it is dangerous to health when used in the dosage or manner, or with the frequency or duration prescribed, recommended, or suggested in the labeling thereof.

99. Because the Defendants each had a statutory duty under 21 U.S.C. § 352 (a) and (f) not to misbrand Pradaxa®, and because each of them violated this duty, they were guilty of negligence per se.

100. Pradaxa® is further misbranded pursuant to 21 C.F.R. § 201.56 because the labeling was not updated as new information became available that caused the labeling to become inaccurate, false, or misleading.

101. Defendants also violated 21 C.F.R. § 201.57 because they failed to identify specific tests needed for selection or monitoring of patients who took the prescription drug Pradaxa®.

102. Defendants violated 21 C.F.R. § 201.57 because the safety considerations regarding Pradaxa® are such that the drug should be reserved for certain situations, and the Defendants failed to state such information.

103. Pradaxa® is mislabeled pursuant to 21 C.F.R. § 201.57 because the labeling fails to describe serious adverse reactions and potential safety hazards, limitations in use imposed by it, and steps that should be taken if they occur.

104. Pradaxa® is mislabeled pursuant to 21 C.F.R. § 201.57 because the labeling was not revised to include a warning as soon as there was reasonable evidence of an association of a serious hazard with the drug (i.e., irreversible bleeding).

105. Pradaxa® is mislabeled pursuant to 21 C.F.R. § 201.57 because the labeling does not state an upper limit dosing beyond which safety and effectiveness have not been established.

106. Pradaxa® violates 21 C.F.R. § 210.122 because the labeling and packaging materials do not meet the appropriate specifications.

107. Pradaxa® violates 21 C.F.R. § 310.303 in that it is not safe and effective for its intended use.

108. Defendants violated 21 C.F.R. §§ 310.305 & 314.80 by failing to report adverse events associated with Pradaxa® as soon as possible or at least within 15 days of the initial receipt by the Defendants of the adverse drug experience.

109. Defendants violated 21 C.F.R. §§ 310.305 & 314.80 by failing to conduct an investigation of each adverse event associated with Pradaxa®, evaluate the cause of the adverse event, submit follow-up reports within the prescribed 15 calendar days of receipt of new information or as requested by the FDA, and keep records of the unsuccessful steps taken to seek additional information regarding serious, unexpected adverse drug experiences.

110. Defendants violated 21 C.F.R. § 314.80 by failing to provide periodic reports to the FDA containing (a) a narrative summary and analysis of the information in the report and an analysis of the IS-day Alert reports submitted during the reporting interval, (b) an Adverse Reaction Report for each adverse drug experience not already reported under the Post marketing IS-day Alert report, (c) a history of actions taken since the last report because of adverse drug experiences (for example, labeling changes or studies initiated) and/or (d) a copy of the published article from scientific or medical journals along with one or more I5-day Alert reports based on information from the scientific literature.

111. Defendants violated 21 C.F.R. § 312.32 because they failed to review all information relevant to the safety of Pradaxa® or otherwise received by Defendants from sources, foreign or domestic, including information derived from any clinical or epidemiological

investigations, animal investigations, commercial marketing experience, reports in the scientific literature, and unpublished scientific papers, as well as reports from foreign regulatory authorities that have not already been previously reported to the agency by the sponsor.

112. Defendants failed to meet the standard of care set by the above statutes and regulations, which were intended for the benefit of individual consumers such as the Plaintiff, making Defendants liable to Plaintiff, and further, because each of them violated the above referenced duties required by these statutes and regulations, they are guilty of negligence per se.

113. Defendant's failure to adequately warn about the magnitude of the risk associated with use of Pradaxa® constitutes negligence per se. This negligence per se proximately caused injury to Plaintiff as described more fully herein.

COUNT VIII
FRAUDULENT CONCEALMENT

114. Plaintiff hereby incorporates by reference all of the above allegations as if fully set forth herein.

115. At all times during the course of dealings between Defendants and Plaintiff, and/or Plaintiff's healthcare providers, and/or the FDA, Defendants misrepresented the safety of Pradaxa® for its intended use.

116. Defendants knew or were reckless in not knowing that their representations were false.

117. In representations to Plaintiff, and/or Plaintiff's healthcare providers, and/or the FDA, Defendants fraudulently concealed and intentionally omitted the following material information:

- a. that Pradaxa® was not as safe or effective as other forms of anticoagulation medication for atrial fibrillation patients;

- b. that Defendants failed to investigate, research, study and consider, fully and adequately, patient weight as a variable factor in establishing recommended dosages of Pradaxa®;
- c. that Defendants failed to investigate, research, study and define, fully and adequately, the safety profile of Pradaxa®;
- d. that Defendants failed to provide adequate warnings that there was no drug, agent or means to reverse the anticoagulation effects of Pradaxa®;
- e. that Defendants failed to include an adequate warning about serious bleeding events associated with Pradaxa®;
- f. that Defendants failed to warn it is difficult or impossible to assess the degree and/or extent of anticoagulation in patients taking Pradaxa®;
- g. that Defendants failed to adequately instruct physicians on how to intervene and/or stabilize a patient who suffers a bleed while taking Pradaxa®;
- h. that it is critical to fully assess renal functioning prior to starting a patient on Pradaxa® and to continue testing and monitoring of renal functioning periodically while the patient is on Pradaxa®;
- i. that there is an increased risk of bleeding events associated with aging patient populations of Pradaxa® users;
- j. that there is an increased risk of gastrointestinal bleeds in those taking Pradaxa®, especially, in those patients with a prior history of gastrointestinal issues and/or upset;

- k. that Pradaxa® was defective, and that it caused dangerous side effects, including but not limited to higher incidence of excessive and/or uncontrollable bleeding;
- l. that Pradaxa® was manufactured negligently;
- m. that Pradaxa® was manufactured defectively;
- n. that Pradaxa® was manufactured improperly;
- o. that Pradaxa® was designed negligently;
- p. that Pradaxa® was designed defectively; and
- q. that Pradaxa® was designed improperly.

118. Defendants were under a duty to disclose to Plaintiff, and Plaintiff's physicians, hospitals, healthcare providers, and/or the FDA the defective nature of Pradaxa®, including but not limited to the heightened risks of excessive and/or uncontrollable bleeding.

119. Defendants had sole access to material facts concerning the defective nature of the product and its propensity to cause serious and dangerous side effects, and hence, cause damage to persons who used Pradaxa®, including the Plaintiff, in particular.

120. Defendants' concealment and omissions of material facts concerning, inter alia, the safety of Pradaxa® was made purposefully, willfully, wantonly, and/or recklessly, to mislead Plaintiff, and Plaintiff's physicians, hospitals and healthcare providers into reliance, continued use of Pradaxa®, and actions thereon, and to cause them to purchase, prescribe, and/or dispense Pradaxa® and/or use the product.

121. Defendants knew that Plaintiff and Plaintiff's physicians, hospitals, healthcare providers, and/or the FDA had no way to determine the truth behind Defendants' concealment

and omissions, and that these included material omissions of facts surrounding Pradaxa®, as set forth herein.

122. Plaintiff, as well as Plaintiff's doctors, healthcare providers, and/or hospitals reasonably relied on facts revealed which negligently, fraudulently and/or purposefully did not include facts that were concealed and/or omitted by Defendants.

123. As a result of the foregoing acts and omissions the Plaintiff was and still is caused to suffer and/or is at a greatly increased risk of serious and dangerous side effects including, inter alia, excessive and/or uncontrollable bleeding, as well as other severe and personal injuries which are permanent and lasting in nature, physical pain and mental anguish, including diminished enjoyment of life.

124. As a result of the foregoing acts and omissions the Plaintiff requires and/or will require more health care and services and did incur medical, health, incidental and related expenses. Plaintiff further alleges that Plaintiff will in the future be required to obtain further medical and/or hospital care, attention, and services.

125. By reason of the foregoing, Plaintiff has been damaged.

COUNT IX
ILLINOIS CONSUMER FRAUD AND DECEPTIVE PRACTICES ACT

126. Plaintiff hereby incorporates by reference all of the above allegations as if fully set forth herein.

127. At all times relevant, the Illinois Consumer Fraud & Deceptive Practices Act, 815 ILCS 505/1 et seq., (hereinafter "IFCA") prohibits "the use of any deception, fraud, false pretense, false promise, misrepresentation or concealment, suppression or omission of any material fact...in the conduct of any trade or commerce" and declares such acts or practices as unlawful.

128. Defendants researched, developed, designed, tested, manufactured, inspected, labeled, distributed, marketed, promoted, sold, and/or otherwise released Pradaxa® into the stream of commerce and in the course of same, directly advertised or marketed the product to health care professionals and consumers, including Plaintiff.

129. Defendants violated the IFCA by the use of deceptive, false, and misleading misrepresentations or omissions of material fact in connection with the marketing, promotion, and sale of Pradaxa®. Defendants communicated, and continue to communicate, the purported benefits and safety of Pradaxa® while failing to disclose the serious and dangerous side effects related to the use of Pradaxa® with the intent that consumers, like Plaintiff, and their healthcare providers rely upon the omissions and misrepresentations and purchase or prescribe Pradaxa®, respectively.

130. Defendants intended that consumers like Plaintiff Jacqueline Boston rely on their deceptive, false and misleading misrepresentations or omissions of material fact in order to increase their sales and profit of Pradaxa®, which was done in the ordinary course of their business.

131. As a result of violating the ICFA, Defendants caused Plaintiff to be prescribed and to use Pradaxa®, causing severe injuries and damages as previously described herein.

132. As a result of Defendants' violation of the ICFA, Plaintiff suffered pecuniary loss and damages, when Plaintiff failed to get the benefit of Plaintiff's bargain by purchasing Pradaxa® in reliance on Defendants' deceptive, false, and misleading representations concerning its benefits and safety, and instead suffered actual severe injuries as previously described herein.

133. Defendants' actions and omissions as identified in this Complaint demonstrate malicious actions and/or intentional disregard of Plaintiff Jacqueline Boston's rights so as to warrant the imposition of punitive damages.

134. Plaintiff relied on Defendants' deceptive, false and misleading misrepresentations or omissions of material fact in order to increase their sales and profits of Pradaxa®, which was done in the ordinary course of their business.

COUNT X
PUNITIVE DAMAGES

135. Plaintiff hereby incorporates by reference all of the above allegations as if fully set forth herein.

136. At all material times, the Defendants knew or should have known that Pradaxa® was inherently dangerous.

137. Despite their knowledge, the Defendants continued to aggressively market Pradaxa® to consumers, including Plaintiff, without disclosing its dangerous side effects when there existed safer alternative products.

138. Despite Defendants' knowledge of Pradaxa®'s defective and unreasonably dangerous nature, Defendants continued to test, design, develop, manufacture, label, package, promote, market, sell and distribute it so as to maximize sales and profits at the expense of the health and safety of the public, including the Plaintiff, in conscious disregard of the foreseeable harm caused by Pradaxa®.

139. Defendants' conduct was intentional and/or wanton.

140. Defendants' conduct as described above, including, but not limited to, their failure to adequately test their product, to provide adequate warnings, and their continued manufacture, sale, and marketing of their products when they knew or should have known of the serious health

risks created, evidences a flagrant disregard of human life as to warrant the imposition of punitive damages as the acts or omissions were committed with knowing, conscious and deliberate disregard for the rights and safety of consumers, including Plaintiff.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff prays for relief as follows:

1. Compensatory damages in excess of the jurisdictional amount, including but not limited to, non-economic damages in excess of \$75,000.
2. Medical expenses and other economic damages in an amount to be determined at trial of this action;
3. Pain and suffering;
4. Non-economic damages for an increased risk of future complications as a direct result of plaintiff's injury;
5. Punitive damages;
6. Prejudgment interest at the highest lawful rate allowed by law;
7. Interest on the judgment at the highest legal rate from the date of judgment until collected;
8. Attorneys' fees, expenses, and costs of this action; and
9. Such further relief as this Court deems necessary, just and proper.

JURY DEMAND

Plaintiff hereby demands a trial by jury on all issues so triable.

Respectfully submitted,

By: /s/ Kristine K. Kraft
Roger C. Denton
Kristine K. Kraft
Megan M. Vanderbeek
SCHLICHTER, BOGARD & DENTON
100 S. 4th Street, Suite 900
St. Louis, MO 63102
Telephone: 314-621-6115
Facsimile: 314-621-7151
rdenton@uselaws.com
kkraft@uselaws.com
mvanderbeek@uselaws.com

ATTORNEYS FOR PLAINTIFF

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON THE REVERSE OF THE FORM.)

I. (a) PLAINTIFFS

Jacqueline Boston

(b) County of Residence of First Listed Plaintiff Randolph County, IL
(EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorney's (Firm Name, Address, and Telephone Number)

Schlichter, Bogard & Denton, 100 S. 4th Street, Ste. 900
St. Louis, MO 63102 314-621-6115

DEFENDANTS

Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer
Ingelheim Corporation, Boehringer Ingelheim USA

County of Residence of First Listed Defendant Fairfield County, CT
(IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE
LAND INVOLVED.

Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- ☐ 1 U.S. Government Plaintiff
☐ 2 U.S. Government Defendant
☐ 3 Federal Question (U.S. Government Not a Party)
☒ 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- | | PTF | DEF | | PTF | DEF |
|---|---------------------------------------|----------------------------|--|----------------------------|---------------------------------------|
| Citizen of This State | <input type="checkbox"/> 1 | <input type="checkbox"/> 1 | Incorporated <i>or</i> Principal Place of Business In This State | <input type="checkbox"/> 4 | <input type="checkbox"/> 4 |
| Citizen of Another State | <input checked="" type="checkbox"/> 2 | <input type="checkbox"/> 2 | Incorporated <i>and</i> Principal Place of Business In Another State | <input type="checkbox"/> 5 | <input checked="" type="checkbox"/> 5 |
| Citizen or Subject of a Foreign Country | <input type="checkbox"/> 3 | <input type="checkbox"/> 3 | Foreign Nation | <input type="checkbox"/> 6 | <input type="checkbox"/> 6 |

IV. NATURE OF SUIT (Place an "X" in One Box Only)

CONTRACT	TORTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
<input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment <input type="checkbox"/> 151 Medicare Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excl. Veterans) <input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability <input type="checkbox"/> 196 Franchise	PERSONAL INJURY <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Federal Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input type="checkbox"/> 360 Other Personal Injury PERSONAL INJURY <input type="checkbox"/> 362 Personal Injury - Med. Malpractice <input checked="" type="checkbox"/> 365 Personal Injury - Product Liability <input type="checkbox"/> 368 Asbestos Personal Injury Product Liability PERSONAL PROPERTY <input type="checkbox"/> 370 Other Fraud <input type="checkbox"/> 371 Truth in Lending <input type="checkbox"/> 380 Other Personal Property Damage <input type="checkbox"/> 385 Property Damage Product Liability	<input type="checkbox"/> 610 Agriculture <input type="checkbox"/> 620 Other Food & Drug <input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881 <input type="checkbox"/> 630 Liquor Laws <input type="checkbox"/> 640 R.R. & Truck <input type="checkbox"/> 650 Airline Regs. <input type="checkbox"/> 660 Occupational Safety/Health <input type="checkbox"/> 690 Other LABOR <input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Mgmt. Relations <input type="checkbox"/> 730 Labor/Mgmt. Reporting & Disclosure Act <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Empl. Ret. Inc. Security Act IMMIGRATION <input type="checkbox"/> 462 Naturalization Application <input type="checkbox"/> 463 Habeas Corpus - Alien Detainee <input type="checkbox"/> 465 Other Immigration Actions	<input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157 PROPERTY RIGHTS <input type="checkbox"/> 820 Copyrights <input type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark SOCIAL SECURITY <input type="checkbox"/> 861 HIA (1395ff) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIWC/DIWW (405(g)) <input type="checkbox"/> 864 SSID Title XVI <input type="checkbox"/> 865 RSI (405(g)) FEDERAL TAX SUITS <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS—Third Party 26 USC 7609	<input type="checkbox"/> 400 State Reapportionment <input type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations <input type="checkbox"/> 480 Consumer Credit <input type="checkbox"/> 490 Cable/Sat TV <input type="checkbox"/> 810 Selective Service <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 875 Customer Challenge 12 USC 3410 <input type="checkbox"/> 890 Other Statutory Actions <input type="checkbox"/> 891 Agricultural Acts <input type="checkbox"/> 892 Economic Stabilization Act <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 894 Energy Allocation Act <input type="checkbox"/> 895 Freedom of Information Act <input type="checkbox"/> 900 Appeal of Fee Determination Under Equal Access to Justice <input type="checkbox"/> 950 Constitutionality of State Statutes
REAL PROPERTY <input type="checkbox"/> 210 Land Condemnation <input type="checkbox"/> 220 Foreclosure <input type="checkbox"/> 230 Rent Lease & Ejectment <input type="checkbox"/> 240 Torts to Land <input type="checkbox"/> 245 Tort Product Liability <input type="checkbox"/> 290 All Other Real Property	CIVIL RIGHTS <input type="checkbox"/> 441 Voting <input type="checkbox"/> 442 Employment <input type="checkbox"/> 443 Housing/Accommodations <input type="checkbox"/> 444 Welfare <input type="checkbox"/> 445 Amer. w/Disabilities - Employment <input type="checkbox"/> 446 Amer. w/Disabilities - Other <input type="checkbox"/> 440 Other Civil Rights PRISONER PETITIONS <input type="checkbox"/> 510 Motions to Vacate Sentence Habeas Corpus: <input type="checkbox"/> 530 General <input type="checkbox"/> 535 Death Penalty <input type="checkbox"/> 540 Mandamus & Other <input type="checkbox"/> 550 Civil Rights <input type="checkbox"/> 555 Prison Condition			

V. ORIGIN

(Place an "X" in One Box Only)

- ☒ 1 Original Proceeding
☐ 2 Removed from State Court
☐ 3 Remanded from Appellate Court
☐ 4 Reinstated or Reopened
☐ 5 Transferred from another district (specify)
☐ 6 Multidistrict Litigation
☐ 7 Appeal to District Judge from Magistrate Judgment

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):
28 USC Section 1332

Brief description of cause:
Product defect resulting in serious personal injury

VII. REQUESTED IN COMPLAINT:

☐ CHECK IF THIS IS A CLASS ACTION UNDER F.R.C.P. 23
DEMAND \$ 75,000.00

CHECK YES only if demanded in complaint:
JURY DEMAND: ☒ Yes ☐ No

VIII. RELATED CASE(S) IF ANY

(See instructions):

JUDGE _____

DOCKET NUMBER _____

DATE

SIGNATURE OF ATTORNEY OF RECORD

05/11/2012

/s/ Kristine Kraft

FOR OFFICE USE ONLY

RECEIPT # _____ AMOUNT _____ APPLYING IFP _____ JUDGE _____ MAG. JUDGE _____

INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

I. (a) Plaintiffs-Defendants. Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.

(b) County of Residence. For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)

(c) Attorneys. Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".

II. Jurisdiction. The basis of jurisdiction is set forth under Rule 8(a), F.R.C.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.

United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here.

United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.

Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.

Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; federal question actions take precedence over diversity cases.)

III. Residence (citizenship) of Principal Parties. This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.

IV. Nature of Suit. Place an "X" in the appropriate box. If the nature of suit cannot be determined, be sure the cause of action, in Section VI below, is sufficient to enable the deputy clerk or the statistical clerks in the Administrative Office to determine the nature of suit. If the cause fits more than one nature of suit, select the most definitive.

V. Origin. Place an "X" in one of the seven boxes.

Original Proceedings. (1) Cases which originate in the United States district courts.

Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. When the petition for removal is granted, check this box.

Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.

Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.

Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.

Multidistrict Litigation. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407. When this box is checked, do not check (5) above.

Appeal to District Judge from Magistrate Judgment. (7) Check this box for an appeal from a magistrate judge's decision.

VI. Cause of Action. Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC 553
Brief Description: Unauthorized reception of cable service

VII. Requested in Complaint. Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.

Demand. In this space enter the dollar amount (in thousands of dollars) being demanded or indicate other demand such as a preliminary injunction.

Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.

VIII. Related Cases. This section of the JS 44 is used to reference related pending cases if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

Date and Attorney Signature. Date and sign the civil cover sheet.